Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck KGaA expands chemicals business with $17bn Sigma-Aldrich buy

This article was originally published in Scrip

Executive Summary

German pharmaceuticals and chemicals group Merck KGaA is to buy R&D chemicals maker Sigma-Aldrich for $140 per share in cash, valuing the US company at around $17bn. Despite the move, Merck chairman Karl-Ludwig Kley disputes any suggestion that Merck is deprioritizing pharmaceuticals.

You may also be interested in...



Merck KGaA To Exit Biosimilars? That Would Be No Surprise To Analysts

Germany's Merck KGaA is reportedly making soundings to sell its biosimilar business to focus on its expanding pipeline.

Merck KGaA To Exit Biosimilars? That Would Be No Surprise To Analysts

Germany's Merck KGaA is reportedly making soundings to sell its biosimilar business to focus on its expanding pipeline.

UK Reimbursement Decisions Focus Mostly On Cancer

The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.

Topics

Related Companies

UsernamePublicRestriction

Register

ID014775

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel